CD4 and tuberculosis: The Haiti study, published in NEJM in 2010, was a randomised, controlled trial that demonstrated reduced mortality and incident tuberculosis (TB) in patients starting ART at a CD4 count threshold of < 350 cells/mm3 (compared with patients waiting to commence therapy at a threshold of < 200 cells/mm3).11